Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048997 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
A Phase 3 study of Lung Cancer, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 356
- Enrollment target
- 14
- Study locations
NCT00048997: Completed Phase 3 study of Lung Cancer, sponsored by Radiation Therapy Oncology Group.
NCT00048997 is a Phase 3 study of Lung Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 356 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (62% lower). The trial reports 14 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00048997, a Phase 3 study of Lung Cancer, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 356 participants
- Enrollment target
- 14
- Study locations
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if giving radiation therapy to the head is effective in preventing CNS metastases in patients who have stage III non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying how well radiation therapy to the head works in preventing CNS metastases in patients who have been previously treated for stage III non-small cell lung cancer.
Primary Outcome
Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. This analysis was planned to occur when all patients had been potentially followed for at least 12 months.
Conditions Studied
Interventions
- OTHER Observation
- RADIATION Radiation therapy
Study Locations (14)
Arizona
- Arizona Oncology Services Foundation - Phoenix
- Virginia G. Piper Cancer Center at Scottsdale Healthcare - Osborn - Scottsdale
- Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea - Scottsdale
Maine
- Central Maine Comprehensive Cancer Center at Central Maine Medical Center - Lewiston
- Maine Center for Cancer Medicine and Blood Disorders - Scarborough - Scarborough
Pennsylvania
- Geisinger Cancer Institute at Geisinger Health - Danville
- Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center - Wilkes-Barre
Illinois
- Resurrection Medical Center - Chicago
Maryland
- Shore Regional Cancer Center at Memorial Hospital - Easton - Easton
Massachusetts
- MetroWest Medical Center - Framingham Union Hospital - Framingham
Michigan
- Josephine Ford Cancer Center at Henry Ford Hospital - Detroit
New Jersey
- Cancer Institute of New Jersey at Cooper University Hospital - Camden - Camden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 356 participants |
| Start Date | 2002-09 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
What the finished NCT00048997 record still lists
NCT00048997 is an interventional study that assigns participants to a tested intervention. The registered 356 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Observation is the first listed.
NCT00048997 lists 14 locations in 10 states (Arizona, Maine, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00048997 about?
NCT00048997 is a clinical study titled "Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if giving radiation therapy to the head is effective in preventing CNS metastases in patients who have stage III non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying how well ...
What is the current status of trial NCT00048997?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 356 participants. The study started on 2002-09. Estimated completion is 2016-12.
What conditions does trial NCT00048997 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00048997?
The interventions under investigation include: Observation (OTHER), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00048997?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00048997 being conducted?
This trial has 14 study locations across Arizona, Illinois, Maine, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00048997's enrollment target sits among peer trials
356 90th of 409 higher than 320 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06077838 · 356 participants · NA
RELAXaHEAD for Headache Patients (Phase III)
- NCT06293469 · 356 participants · NA
Accelerated Flap Coverage in Severe Lower Extremity Trauma
- NCT06958328 · 356 participants · Phase 3
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
- NCT06960993 · 356 participants · NA
Mosaic Trial for Stem Cell Transplant Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia